Education
About Us
Working with TipRanks
Follow Us
Veracyte Inc (VCYT)
:VCYT
Earnings Data
Report Date
Mar 02, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
0.38Last Year’s EPS
0.06Same Quarter Last Year
Moderate Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Veracyte delivered a strong quarter with record revenue growth and profitability, driven by robust performance from its core testing business, particularly Decipher and Afirma. The company achieved a significant milestone by reaching its adjusted EBITDA margin target ahead of schedule. However, challenges remain in the form of declining biopharmaceutical revenue, competitive pressures from new technologies, and a slight decrease in testing ASP.Company Guidance
Record Revenue Growth
Veracyte reported total revenue growth of 14% year-over-year to approximately $132 million in Q3 2025. Core testing business revenue grew by 18%, with significant contributions from Decipher (26% volume growth) and Afirma (13% volume growth).
Strong Profitability
Adjusted EBITDA margin reached a record 30%, representing a 650 basis point improvement from the prior year. This performance was well ahead of expectations, with the company achieving its goal of a 25% adjusted EBITDA margin more than a year ahead of internal plans.
Decipher's Clinical Utility and Growth
Decipher delivered approximately 26,700 tests in Q3, marking the 14th consecutive quarter of over 25% year-over-year volume growth. The test is increasingly recognized by physicians for its clinical utility across all risk categories, particularly in high-risk localized and metastatic patients.
Afirma's Continued Success
Afirma achieved 13% volume growth in Q3 2025, driven by new account wins and increased utilization per account. The operational efficiency program is progressing well, with a transition to a new transcriptome workflow expected to be completed by year-end.
Positive Financial Outlook
Veracyte raised its 2025 total revenue guidance to $506 million to $510 million, up from previous guidance. The adjusted EBITDA margin guidance was also raised to exceed 25% for the year.
VCYT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
VCYT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 04, 2025 | $36.12 | $46.04 | +27.46% |
Aug 06, 2025 | $23.97 | $27.68 | +15.48% |
May 07, 2025 | $30.84 | $31.21 | +1.20% |
Feb 24, 2025 | $39.36 | $33.46 | -14.99% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Veracyte Inc (VCYT) report earnings?
Veracyte Inc (VCYT) is schdueled to report earning on Mar 02, 2026, After Close (Confirmed).
What is Veracyte Inc (VCYT) earnings time?
Veracyte Inc (VCYT) earnings time is at Mar 02, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VCYT EPS forecast?
VCYT EPS forecast for the fiscal quarter 2025 (Q4) is 0.38.